Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study.
Identifieur interne : 002075 ( PubMed/Corpus ); précédent : 002074; suivant : 002076Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study.
Auteurs : William J. Sandborn ; Jean-Frédéric Colombel ; Subrata Ghosh ; Bruce E. Sands ; Gerald Dryden ; Xavier Hébuterne ; Rupert W. Leong ; Brian Bressler ; Thomas Ullman ; Peter L. Lakatos ; Walter Reinisch ; Li-An Xu ; Allison LuoSource :
- Journal of Crohn's & colitis [ 1876-4479 ] ; 2016.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Antibodies, Monoclonal (therapeutic use), Chemokine CXCL10 (antagonists & inhibitors), Colitis, Ulcerative (drug therapy), Female, Gastrointestinal Agents (administration & dosage), Gastrointestinal Agents (therapeutic use), Humans, Infusions, Intravenous, Male, Middle Aged, Remission Induction, Young Adult.
- MESH :
- chemical , administration & dosage : Gastrointestinal Agents.
- chemical , antagonists & inhibitors : Chemokine CXCL10.
- chemical , therapeutic use : Antibodies, Monoclonal, Gastrointestinal Agents.
- drug therapy : Colitis, Ulcerative.
- Adolescent, Adult, Aged, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Remission Induction, Young Adult.
Abstract
Interferon-γ-inducible protein-10 [IP-10] mediates immune cell trafficking from the circulation to the inflamed colon and decreases gut epithelial cell survival. IP-10 expression is increased in patients with ulcerative colitis [UC]. We report efficacy and safety results from a dose-ranging induction study of eldelumab, a fully human monoclonal antibody to IP-10, in moderately to severely active UC.
DOI: 10.1093/ecco-jcc/jjv224
PubMed: 26721935
Links to Exploration step
pubmed:26721935Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study.</title><author><name sortKey="Sandborn, William J" sort="Sandborn, William J" uniqKey="Sandborn W" first="William J" last="Sandborn">William J. Sandborn</name><affiliation><nlm:affiliation>Inflammatory Bowel Disease Center, University of California San Diego, La Jolla, CA, USA wsandborn@ucsd.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Colombel, Jean Frederic" sort="Colombel, Jean Frederic" uniqKey="Colombel J" first="Jean-Frédéric" last="Colombel">Jean-Frédéric Colombel</name><affiliation><nlm:affiliation>Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ghosh, Subrata" sort="Ghosh, Subrata" uniqKey="Ghosh S" first="Subrata" last="Ghosh">Subrata Ghosh</name><affiliation><nlm:affiliation>Department of Medicine, University of Calgary, Calgary, AB, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Sands, Bruce E" sort="Sands, Bruce E" uniqKey="Sands B" first="Bruce E" last="Sands">Bruce E. Sands</name><affiliation><nlm:affiliation>Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Dryden, Gerald" sort="Dryden, Gerald" uniqKey="Dryden G" first="Gerald" last="Dryden">Gerald Dryden</name><affiliation><nlm:affiliation>Division of Gastroenterology, Hepatology, and Nutrition, University of Louisville School of Medicine, Louisville, KY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hebuterne, Xavier" sort="Hebuterne, Xavier" uniqKey="Hebuterne X" first="Xavier" last="Hébuterne">Xavier Hébuterne</name><affiliation><nlm:affiliation>Faculté de Médecine, Université de Nice-Sophia Antipolis, Hôpital de l'Archet, Nice, France.</nlm:affiliation></affiliation></author><author><name sortKey="Leong, Rupert W" sort="Leong, Rupert W" uniqKey="Leong R" first="Rupert W" last="Leong">Rupert W. Leong</name><affiliation><nlm:affiliation>Concord Hospital, Gastroenterology and Liver Services, University of New South Wales, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Bressler, Brian" sort="Bressler, Brian" uniqKey="Bressler B" first="Brian" last="Bressler">Brian Bressler</name><affiliation><nlm:affiliation>Division of Gastroenterology, St Paul's Hospital, Vancouver, BC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Ullman, Thomas" sort="Ullman, Thomas" uniqKey="Ullman T" first="Thomas" last="Ullman">Thomas Ullman</name><affiliation><nlm:affiliation>Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Lakatos, Peter L" sort="Lakatos, Peter L" uniqKey="Lakatos P" first="Peter L" last="Lakatos">Peter L. Lakatos</name><affiliation><nlm:affiliation>1st Department of Medicine, Semmelweis University, Budapest, Hungary.</nlm:affiliation></affiliation></author><author><name sortKey="Reinisch, Walter" sort="Reinisch, Walter" uniqKey="Reinisch W" first="Walter" last="Reinisch">Walter Reinisch</name><affiliation><nlm:affiliation>Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, and McMaster University, Department of Internal Medicine, Hamilton, ON, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Xu, Li An" sort="Xu, Li An" uniqKey="Xu L" first="Li-An" last="Xu">Li-An Xu</name><affiliation><nlm:affiliation>Bristol-Myers Squibb, Lawrenceville, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Luo, Allison" sort="Luo, Allison" uniqKey="Luo A" first="Allison" last="Luo">Allison Luo</name><affiliation><nlm:affiliation>Formerly of Bristol-Myers Squibb, Lawrenceville, NJ, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26721935</idno><idno type="pmid">26721935</idno><idno type="doi">10.1093/ecco-jcc/jjv224</idno><idno type="wicri:Area/PubMed/Corpus">002075</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002075</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study.</title><author><name sortKey="Sandborn, William J" sort="Sandborn, William J" uniqKey="Sandborn W" first="William J" last="Sandborn">William J. Sandborn</name><affiliation><nlm:affiliation>Inflammatory Bowel Disease Center, University of California San Diego, La Jolla, CA, USA wsandborn@ucsd.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Colombel, Jean Frederic" sort="Colombel, Jean Frederic" uniqKey="Colombel J" first="Jean-Frédéric" last="Colombel">Jean-Frédéric Colombel</name><affiliation><nlm:affiliation>Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ghosh, Subrata" sort="Ghosh, Subrata" uniqKey="Ghosh S" first="Subrata" last="Ghosh">Subrata Ghosh</name><affiliation><nlm:affiliation>Department of Medicine, University of Calgary, Calgary, AB, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Sands, Bruce E" sort="Sands, Bruce E" uniqKey="Sands B" first="Bruce E" last="Sands">Bruce E. Sands</name><affiliation><nlm:affiliation>Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Dryden, Gerald" sort="Dryden, Gerald" uniqKey="Dryden G" first="Gerald" last="Dryden">Gerald Dryden</name><affiliation><nlm:affiliation>Division of Gastroenterology, Hepatology, and Nutrition, University of Louisville School of Medicine, Louisville, KY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hebuterne, Xavier" sort="Hebuterne, Xavier" uniqKey="Hebuterne X" first="Xavier" last="Hébuterne">Xavier Hébuterne</name><affiliation><nlm:affiliation>Faculté de Médecine, Université de Nice-Sophia Antipolis, Hôpital de l'Archet, Nice, France.</nlm:affiliation></affiliation></author><author><name sortKey="Leong, Rupert W" sort="Leong, Rupert W" uniqKey="Leong R" first="Rupert W" last="Leong">Rupert W. Leong</name><affiliation><nlm:affiliation>Concord Hospital, Gastroenterology and Liver Services, University of New South Wales, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Bressler, Brian" sort="Bressler, Brian" uniqKey="Bressler B" first="Brian" last="Bressler">Brian Bressler</name><affiliation><nlm:affiliation>Division of Gastroenterology, St Paul's Hospital, Vancouver, BC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Ullman, Thomas" sort="Ullman, Thomas" uniqKey="Ullman T" first="Thomas" last="Ullman">Thomas Ullman</name><affiliation><nlm:affiliation>Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Lakatos, Peter L" sort="Lakatos, Peter L" uniqKey="Lakatos P" first="Peter L" last="Lakatos">Peter L. Lakatos</name><affiliation><nlm:affiliation>1st Department of Medicine, Semmelweis University, Budapest, Hungary.</nlm:affiliation></affiliation></author><author><name sortKey="Reinisch, Walter" sort="Reinisch, Walter" uniqKey="Reinisch W" first="Walter" last="Reinisch">Walter Reinisch</name><affiliation><nlm:affiliation>Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, and McMaster University, Department of Internal Medicine, Hamilton, ON, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Xu, Li An" sort="Xu, Li An" uniqKey="Xu L" first="Li-An" last="Xu">Li-An Xu</name><affiliation><nlm:affiliation>Bristol-Myers Squibb, Lawrenceville, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Luo, Allison" sort="Luo, Allison" uniqKey="Luo A" first="Allison" last="Luo">Allison Luo</name><affiliation><nlm:affiliation>Formerly of Bristol-Myers Squibb, Lawrenceville, NJ, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of Crohn's & colitis</title><idno type="eISSN">1876-4479</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Chemokine CXCL10 (antagonists & inhibitors)</term><term>Colitis, Ulcerative (drug therapy)</term><term>Female</term><term>Gastrointestinal Agents (administration & dosage)</term><term>Gastrointestinal Agents (therapeutic use)</term><term>Humans</term><term>Infusions, Intravenous</term><term>Male</term><term>Middle Aged</term><term>Remission Induction</term><term>Young Adult</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Gastrointestinal Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Chemokine CXCL10</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Gastrointestinal Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Colitis, Ulcerative</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Infusions, Intravenous</term><term>Male</term><term>Middle Aged</term><term>Remission Induction</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Interferon-γ-inducible protein-10 [IP-10] mediates immune cell trafficking from the circulation to the inflamed colon and decreases gut epithelial cell survival. IP-10 expression is increased in patients with ulcerative colitis [UC]. We report efficacy and safety results from a dose-ranging induction study of eldelumab, a fully human monoclonal antibody to IP-10, in moderately to severely active UC.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26721935</PMID><DateCreated><Year>2016</Year><Month>03</Month><Day>30</Day></DateCreated><DateCompleted><Year>2016</Year><Month>12</Month><Day>30</Day></DateCompleted><DateRevised><Year>2017</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-4479</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of Crohn's & colitis</Title><ISOAbbreviation>J Crohns Colitis</ISOAbbreviation></Journal><ArticleTitle>Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study.</ArticleTitle><Pagination><MedlinePgn>418-28</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/ecco-jcc/jjv224</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">Interferon-γ-inducible protein-10 [IP-10] mediates immune cell trafficking from the circulation to the inflamed colon and decreases gut epithelial cell survival. IP-10 expression is increased in patients with ulcerative colitis [UC]. We report efficacy and safety results from a dose-ranging induction study of eldelumab, a fully human monoclonal antibody to IP-10, in moderately to severely active UC.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 252 adults with UC [Mayo score ≥ 6 and endoscopic subscore ≥ 2] were randomised 1:1:1 to placebo or eldelumab 15 or 25 mg/kg administered intravenously on Days 1 and 8 and every other week thereafter. The primary endpoint was clinical remission [Mayo score ≤ 2; no individual subscale score > 1] at Week 11. Key secondary endpoints included Mayo score clinical response and mucosal healing at Week 11.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Neither eldelumab 15 or 25 mg/kg resulted in significant increases vs placebo in the proportion of patients achieving Week 11 clinical remission. Remission and response rates were 17.6% and 47.1% with eldelumab 25mg/kg, 13.1% and 44.0% with eldelumab 15mg/kg, and 9.6% and 31.3% with placebo. Clinical remission and response rates were higher in anti-tumour necrosis factor [TNF]-naïve patients treated with eldelumab compared with placebo. Eldelumab treatment was well tolerated and no immunogenicity was observed.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The primary endpoint was not achieved with induction treatment with eldelumab 15 or 25 mg/kg in patients with UC. Trends towards clinical remission and response were observed in the overall population and were more pronounced in anti-TNF naïve patients. Eldelumab safety signals were consistent with those reported previously [ClinicalTrials.gov number, NCT01294410].</AbstractText><CopyrightInformation>Copyright © 2015 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sandborn</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Inflammatory Bowel Disease Center, University of California San Diego, La Jolla, CA, USA wsandborn@ucsd.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colombel</LastName><ForeName>Jean-Frédéric</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Subrata</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Calgary, Calgary, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sands</LastName><ForeName>Bruce E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dryden</LastName><ForeName>Gerald</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Hepatology, and Nutrition, University of Louisville School of Medicine, Louisville, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hébuterne</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Faculté de Médecine, Université de Nice-Sophia Antipolis, Hôpital de l'Archet, Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leong</LastName><ForeName>Rupert W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Concord Hospital, Gastroenterology and Liver Services, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bressler</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, St Paul's Hospital, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ullman</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lakatos</LastName><ForeName>Peter L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>1st Department of Medicine, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinisch</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, and McMaster University, Department of Internal Medicine, Hamilton, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Li-An</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Bristol-Myers Squibb, Lawrenceville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Allison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Formerly of Bristol-Myers Squibb, Lawrenceville, NJ, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01294410</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>12</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Crohns Colitis</MedlineTA><NlmUniqueID>101318676</NlmUniqueID><ISSNLinking>1873-9946</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C114753">CXCL10 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054357">Chemokine CXCL10</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005765">Gastrointestinal Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000613134">eldelumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Gut. 2011 Jun;60(6):780-7</RefSource><PMID Version="1">21209123</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pathol Int. 2007 Jul;57(7):413-20</RefSource><PMID Version="1">17587240</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Gastroenterol. 2014 Apr 23;14:80</RefSource><PMID Version="1">24758588</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Inflamm Bowel Dis. 2005 Sep;11(9):799-805</RefSource><PMID Version="1">16116313</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Immunol. 2002 Nov;32(11):3197-205</RefSource><PMID Version="1">12555665</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Inflamm Bowel Dis. 2009 Apr;15(4):581-8</RefSource><PMID Version="1">19067414</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Crohns Colitis. 2008 Sep;2(3):219-25</RefSource><PMID Version="1">21172214</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2013 Aug 22;369(8):699-710</RefSource><PMID Version="1">23964932</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2006 Feb;130(2):323-33; quiz 591</RefSource><PMID Version="1">16472588</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2007 Jan;132(1):52-65</RefSource><PMID Version="1">17241859</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Dig Dis Sci. 2010 Apr;55(4):1044-52</RefSource><PMID Version="1">20155319</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gut. 2013 Nov;62(11):1642-52</RefSource><PMID Version="1">24104885</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2007 Feb;132(2):516-26</RefSource><PMID Version="1">17258720</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2005 Dec 8;353(23):2462-76</RefSource><PMID Version="1">16339095</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2003 Aug 1;171(3):1401-6</RefSource><PMID Version="1">12874231</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gut. 2014 Mar;63(3):442-50</RefSource><PMID Version="1">23461895</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1987 Dec 24;317(26):1625-9</RefSource><PMID Version="1">3317057</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gastroenterol Nurs. 2012 Jan-Feb;35(1):54-63</RefSource><PMID Version="1">22306730</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Dig Dis Sci. 2008 Apr;53(4):875-91</RefSource><PMID Version="1">17934839</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2004 May;126(6):1504-17</RefSource><PMID Version="1">15168363</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cochrane Database Syst Rev. 2012 Sep 12;(9):CD000478</RefSource><PMID Version="1">22972046</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2012 Nov 3;380(9853):1606-19</RefSource><PMID Version="1">22914296</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Pathol. 1999 Aug;155(2):331-6</RefSource><PMID Version="1">10433925</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2001 Oct 11;345(15):1098-104</RefSource><PMID Version="1">11596589</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2014 Jul 26;384(9940):309-18</RefSource><PMID Version="1">24814090</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Aliment Pharmacol Ther. 2005 Jul 1;22(1):1-16</RefSource><PMID Version="1">15963074</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Gastroenterol. 1988 Jun;10(3):306-10</RefSource><PMID Version="1">2980766</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 2007 Jun 19;146(12):829-38</RefSource><PMID Version="1">17470824</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 2012 Jan;142(1):46-54.e42; quiz e30</RefSource><PMID Version="1">22001864</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Gastroenterology. 1989 Mar;96(3):804-10</RefSource><PMID Version="1">2644154</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Gastroenterol. 2011 Apr;106(4):601-16</RefSource><PMID Version="1">21407188</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054357" MajorTopicYN="N">Chemokine CXCL10</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003093" MajorTopicYN="N">Colitis, Ulcerative</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005765" MajorTopicYN="N">Gastrointestinal Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4946756 [Available on 04/01/17]</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Inflammatory bowel diseases</Keyword><Keyword MajorTopicYN="N">ulcerative colitis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>09</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26721935</ArticleId><ArticleId IdType="pii">jjv224</ArticleId><ArticleId IdType="doi">10.1093/ecco-jcc/jjv224</ArticleId><ArticleId IdType="pmc">PMC4946756</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002075 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002075 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26721935
|texte= Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26721935" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |